Synapse - Owen O'connor

Results (98)

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging: Research paper

Journal Article

Moskowitz, C. H.; Yahalom, J.; Zelenetz, A. D.; Zhang, Z.; Filippa, D.; Teruya-Feldstein, J.; Kewalramani, T.; Moskowitz, A. J.; Rice, R.; Maragulia, J.; more...
British Journal of Haematology (2010)

Fulltext@MSK | Save

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma

Journal Article

Moskowitz, C. H.; Schoder, H.; Teruya-Feldstein, J.; Sima, C.; Iasonos, A.; Portlock, C. S.; Straus, D.; Noy, A.; Palomba, M. L.; O'Connor, O. A.; more...
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma

Meeting Abstract

Caces, D. D.; Halaas, J.; Hamlin, P.; Noy, A.; Kewalramani, T.; Portlock, C. S.; Zelenetz, A. D.; O'Connor, O. A.; Gerecitano, J. F.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Prediction of treatment response in subtypes of non-Hodgkin's lymphoma by in vivo (31)P MR spectroscopy before treatment

Meeting Abstract

Arias-Mendoza, F.; Leach, M. O.; Koutcher, J. A.; Griffiths, J. R.; Heerschap, A.; Glickson, J. D.; O'Connor, O. A.; Brown, T. R.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies

Meeting Abstract

Wilson, W. H.; Czuczman, M. S.; LaCasce, A. S.; Gerecitano, J. F.; Leonard, J. P.; Dunleavy, K.; Krivoshik, A. P.; Xiong, H.; Chiu, Y.; O'Connor, O. A.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas

Meeting Abstract

Gerecitano, J. F.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D. J.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

Journal Article

O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Straus, D.; Hamlin, P.; Stubblefield, M.; Dumitrescu, O.; Colevas, A. D.; Grant, B.; Zelenetz, A.
British Journal of Haematology (2008)

Fulltext@MSK | Save

Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses

Meeting Abstract

Stewart, K. A.; O'Connor, O. A.; Alsina, M.; Trudel, S.; Urquilla, P. R.; Vallone, M. K.; Molineaux, C. J.; Goy, A.; Orlowski, R. Z.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Targeting anti-apoptotic bcl-2 family members with ABT-737 compliments the activity of bortezomib and conventional agents in in vitro models of lymphoproliferative malignancies

Meeting Abstract

Paoluzzi, L.; Gonen, M.; Gardner, J. R.; Heaney, M.; O'Connor, O. A.
Cancer Research (2007)

Fulltext@MSK | Save

A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

Meeting Abstract

O'Connor, O. A.; Hamlin, P.; Portlock, C.; Moskowitz, C.; Noy, A.; Straus, D.; Dumetrescu, O.; Sarasohn, D.; Neylon, E.; Hamelers, R.; more...
Molecular Cancer Therapeutics (2007)

Fulltext@MSK | Save